Sartorius Stedim Biotech S.A.
SRTOY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.27 | -1.14 | 0.27 | 3.60 |
| FCF Yield | 2.59% | 0.68% | 0.68% | 1.05% |
| EV / EBITDA | 30.66 | 34.98 | 20.82 | 43.93 |
| Quality | ||||
| ROIC | 4.09% | 5.48% | 19.11% | 14.82% |
| Gross Margin | 43.41% | 44.44% | 52.52% | 53.79% |
| Cash Conversion Ratio | 3.72 | 2.03 | 0.54 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.33% | -1.30% | 22.28% | 26.08% |
| Free Cash Flow Growth | 204.48% | -14.09% | -51.15% | 44.35% |
| Safety | ||||
| Net Debt / EBITDA | 3.27 | 4.72 | 0.77 | 0.49 |
| Interest Coverage | 2.33 | 4.00 | 24.27 | 65.71 |
| Efficiency | ||||
| Inventory Turnover | 2.30 | 1.75 | 1.62 | 1.70 |
| Cash Conversion Cycle | 122.00 | 186.30 | 213.96 | 192.47 |